Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Indian Rupee: RBI FX steps support INR but raise hedging costs – MUFG

MUFG’s Michael Wan explains that recent RBI FX measures have supported spot Indian Rupee, while temporarily disrupting derivatives liquidity. Offshore INR forward premiums fell sharply after restrictions on non-resident NDF access and higher hedge costs. These actions reduced speculative Dollar demand and helped INR rally, though at the expense of wider bid-ask spreads and less liquid onshore…

Indian Rupee: RBI FX steps support INR but raise hedging costs – MUFG

Recent RBI FX measures have supported the spot Indian Rupee (INR) by reaching the 95.2 level, but have also increased hedging costs, according to MUFG's Michael Wan. The actions include restrictions on non-resident Non-Deliverable Forwards (NDF) access and higher hedge costs, which led to a sharp decline in offshore INR forward premiums.

This move reduced speculative Dollar demand and helped INR rally, although it resulted in wider bid-ask spreads and less liquid onshore forwards. While the RBI confirmed that the 20% cash-margin requirement covered interbank trades, the temporary withdrawal of USD/INR forward quotes due to uncertainty added to market concerns. The uncertainty over hedge costs and potential widening bid-ask spreads could lead to cautious market-making, further widening spreads and shifting activity offshore.

Market participants noted that offshore INR forward premiums fell sharply across all tenors between October 12 and 13, suggesting a rapid unwinding of offshore demand for INR downside protection after the RBI's measures. The overall effect of these actions was a rally in INR, albeit at the expense of higher hedging expenses and less liquid onshore forward markets.

Written by urgent.news from FXStreet's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at fxstreet.com →

More in Finance & Markets

[Yuhan] Proof needed for Lazertinib numbers and subsequent growth narrative

The author is an analyst for NH Investment & Securities. He can be reached at seungyeon.han@nhsec.com -- Ed.Three pre-conditions for sustained rebound: Defensiveness, royalties, and global L/O dealsWe…

  • Yuhan maintains Buy rating and W110,000 target price from NH Investment & Securities
  • PALOMA-2 trial showed ORR of 90%, mPFS of 26.1 months, and 3-year OS rate of 70%

More from Wednesday 14 October →